Board of Directors
Peter Maag, Chief Executive Officer, XDx, Inc.
Dr. Peter Maag is the Chief Executive Officer for XDx, Inc. Dr. Maag has over 20 years of Executive Management experience in the pharmaceutical and diagnostic industry. Prior to joining XDx, Dr. Maag was President Novartis Diagnostics based in Emeryville, CA. He headed the expansion of the unit with growth in global markets in its blood screening business and established new ventures in molecular diagnostics. Dr. Maag also led one of Novartis’ key affiliates as Country President, Germany and lived in a dynamically growing emerging market as Country President, Korea. At Novartis headquarters in Switzerland, He helped the setup of the Infectious Diseases Franchise and served as the Head of Strategy for Novartis Pharmaceuticals. Prior to joining Novartis, Dr. Maag worked for 6 years at McKinsey & Company in New Jersey and Germany, focusing on pharmaceuticals and globalization strategies. Supporting various Healthcare and High Tech companies in their growth efforts, he holds board and advisory positions at Phoenix, Microsonic Systems, and Cobaltix. Dr. Maag studied pharmaceutical sciences in Heidelberg and London and received his Ph.D. from the University of Berlin, Germany.
Michael D. Goldberg, Chairman of the Board, XDx, Inc.
Michael Goldberg is Chairman of XDx, Inc. During a career spanning 30 years, he has been a company founder, CEO, board member and venture capitalist. Michael joined the life science industry in 1981 and participated in the commercialization of the first generation of recombinant DNA, monoclonal antibody and PCR technology. Michael has been a pioneer in developing and building molecular diagnostics companies and has served on the boards of Genomic Health, CardioDx, and Crescendo Bioscience. Michael joined the XDx board in 2011 to assist in the commercialization AlloMap and to extend the XDx technology platform to other important clinical applications in transplant medicine and immunology. In addition to his work as a corporate board member and investor, Michael has served on the Board of the California Institute for Regenerative Medicine since its inception in 2005 ($3 billion state stem cell agency). Michael is also on the advisory councils of the Harvard Center for Genetics and Genomics, the Stanford Neuroscience Institute, the Caltech Division of Biology, and the Berkeley Center for Law and Technology. He is a member of the Personalized Medicine Coalition and an honorary trustee of the National Childhood Cancer Foundation. Michael is a former board member of the Western Association of Venture Capitalists. Michael holds a BA from Brandeis University and an MBA from the Stanford Graduate School of Business.
Dr. Peter Altman, President and CEO, BioCardia, Inc.
Peter is President and CEO of BioCardia, Inc., a developer of investigational cardiovascular biotherapeutic delivery systems and FDA cleared interventional catheter systems. These systems currently enable investigational clinical studies of cell and gene transplantation therapies to treat myocardial infarction, heart failure, and ischemia. Peter was the founding president and CEO for XDx. He was founding CEO at Lumen Therapeutics, a developer of drugs to treat cardiac bypass graft hyperplasia. Previously, Peter was with Ventritex (acquired by St Jude Medical and became their Cardiac Rhythm Management division). Peter received his Ph.D. in bioengineering/pharmaceutical chemistry from the University of California San Francisco and University of California Berkeley, his Management of Technology certificate from the Haas School of Business, University of California Berkeley, and both his master of science and bachelors of science degrees in mechanical engineering from the Columbia University School of Engineering and Applied Sciences. Peter has been elected a Fellow of the American Heart Association.
G. Steven Burrill, CEO, Burrill & Company
G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. An early pioneer, Mr. Burrill is one of the original architects of the industry and one of its most avid and sustained developers. He currently serves as chairman of the board of Pharmasset, and is a member of the boards of directors of Catalyst Biosciences, DepoMed (Amex: DMI), Targacept (NASDAQ: TRGT), Proventys and Phytomedics. Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide. In 2002, Mr. Burrill was recognized as the biotech investment visionary by the prestigious Scientific American magazine (The Scientific American 50). Mr. Burrill is a founder of the Foundation for the National Medals of Science and Technology and currently serves on its board of directors. Some of his not for profit activities include serving on the board of directors for the Bay Area Science Infrastructure Consortium, BayBio, the California Healthcare Institute, the Exploratorium, The Kellogg Center for Biotechnology, Research America, Campaign for Medical Research, The National Health Museum, and the University of California, San Francisco (UCSF) Foundation. He is also the chairman of the Mayor’s Biotech Advisory Committee (MAYBAC).
Brook Byers, Partner, Kleiner Perkins Caufield & Byers
Brook Byers has been a venture capital investor since 1972 and in 1984 he formed the first life science practice group in the venture capital profession to help Kleiner Perkins Caufield & Byers (KPCB) become a premier venture firm in the medical, health care and biotechnology fields. KPCB has invested in and helped build over 110 life sciences companies which have already developed hundreds of products to treat major underserved medical needs for millions of patients. Brook is currently a board member of nine companies including XDx. He was formerly a director of IDEC Pharmaceuticals (chairman), Athena Neurosciences (chairman), Signal Pharmaceuticals, Arris Pharmaceuticals, Pharmacopeia, Ligand Pharmaceuticals (chairman), Insite Vision, Hybritech (chairman), Genprobe, Nanogen, and others. Brook was president and a director of the Western Association of Venture Capitalists and is a contributing author to the book “Guide to Venture Capital”. Raised in Atlanta, Georgia, Brook graduated in electrical engineering from Georgia Tech and received an M.B.A. from Stanford Graduate School of Business. He serves the community as a trustee of various schools, museums and foundations including UCSF Medical Center, the California Healthcare Institute and the New Schools Foundation.
Dr. Fred Cohen, Managing Director, TPG Ventures
Fred is a managing director at TPG (Texas Pacific Group) Ventures. He also retains a position as a professor of cellular and molecular pharmacology at the University of California, San Francisco. Fred also serves as a member of the boards of GenomicHealth, XDx, Kemia, Five Prime Therapeutics and Matrix Pharmaceuticals. He is also a member of the investment committee of the board of Quintiles Transnational. He received his M.D. from Stanford in 1984, his D.Phil. from Oxford as a Rhodes Scholar in 1980 and his B.S. in 1978 from Yale University. Fred has been a member of the faculty of UCSF since 1986 and is best known for his work on protein structure and the conformational basis of prion disease.
Vijay Lathi, Managing Director, New Leaf Venture Partners
Vijay Lathi is a managing director of New Leaf Venture Partners, a healthcare focused venture capital firm formed by the healthcare team formerly at Sprout Group. He currently sits on the board of directors of Aviir, Relypsa, Kalypsys, Neurovista, Proteogenix, and XDx. Vijay joined Sprout in 1998 after working as an analyst in the Healthcare Venture Capital Group at Robertson Stephens & Co. and Cornerstone Research. Vijay graduated from the Massachusetts Institute of Technology and Stanford University where he received his B.S. and M.S. in chemical engineering, with an emphasis on the application of engineering to life science technology. Vijay is also a member of AIChE.
David Levison, CEO, CardioDX
David is the founder, President, and CEO of CardioDx . Prior to founding CardioDx, David was a venture partner at TPG Ventures, where he was the interim CEO of XDx. Previously, he was the founder, president and CEO of iScribe (which was sold to AdvancePCS-now Caremark in December, 2001). Prior to iScribe, David was president of Oncology Therapeutics Network (sold to Bristol-Myers Squibb in 1996). David also served as CFO of OTN's parent company, Axion, from 1990 to 1993. Prior to Axion, he was with Cole Gilburne Fund, an early stage, technology focused venture capital firm. David received his MBA from Stanford University and B.S. from Williams College.
Dr. Ralph Snyderman, Chancellor Emeritus and James B. Duke Professor of Medicine Duke University
Dr. Ralph Snyderman is chancellor emeritus and James B. Duke Professor of Medicine at Duke University. Prior to that, he served as chancellor for health affairs, executive dean of the School of Medicine, and president and chief executive officer of the Duke University Health System, one of the few fully integrated health systems in the country. Dr. Snyderman led the transition of this excellent medical center into an internationally recognized model for academic medicine. During his tenure, the medical school and hospital ranked amongst the nation's best. Dr. Snyderman was senior vice president for medical research and development at Genentech, Inc. Dr. Snyderman received his M.D., magna cum laude, in 1965 from the Downstate Medical Center of the State University of New York and he served his internship and residency in medicine at Duke. Pre-eminent in his field of immunology, Dr. Snyderman is internationally recognized for his research contributions to our understanding of inflammation that have led to numerous important discoveries published in nearly 350 manuscripts over the last 25 years. Additionally, Dr. Snyderman serves as a member of the board of directors of Procter and Gamble Inc. as well as several other boards.